Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease

Area of Science:

• Nephrology
• Orthopedics
• Bone Metabolism

Background:

• Patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), including those on hemodialysis, exhibit a significantly higher risk of fractures and related mortality compared to individuals with normal kidney function.
• Bone fragility assessment in CKD patients is challenging due to the complex pathophysiology of uremia-related bone fragility, which differs from typical osteoporosis.
• Multiple uremia-associated factors, such as severe secondary hyperparathyroidism, parathyroid hormone resistance, and mineralization defects, contribute to bone fragility in CKD.

Purpose of the Study:

• To review the prevalence of fractures in patients with CKD-MBD.
• To examine the interplay between CKD-MBD and osteoporosis in this patient population.
• To discuss factors contributing to impaired bone mechanical properties in CKD.

Main Methods:

• Literature review focusing on CKD-MBD, osteoporosis, and bone fragility.
• Analysis of factors influencing bone microarchitecture and material properties in CKD.
• Synthesis of current understanding regarding fracture risk and contributing elements in CKD patients.

Main Results:

• CKD patients experience elevated fracture rates and associated mortality.
• Uremia exacerbates bone fragility through mechanisms including altered bone cell function and oxidative stress.
• Complex interactions between CKD-MBD, secondary hyperparathyroidism, and osteoporosis contribute to bone deterioration.

Conclusions:

• Fracture prevention is a critical but often overlooked aspect of CKD-MBD management.
• Uremia-induced changes significantly compromise bone quality and increase fracture risk.
• Further research is needed to elucidate the multifactorial contributors to bone fragility in CKD.